Majid Marjani - Concepedia

Author

Majid Marjani

Also Known As

Agnes Linglart, David C. Lye, Homa Hatefi Minaei, Jalaledin Ghanavi, José M. Lorenzo-Salazar, M F Al Marjani, M Marjani, M. MARJANI, M. Marjani, Majid Marjani

270

Publications

8.3K

Citations

H-Index

120

Concepts

All Affiliations

Masih Daneshvari Hospital Shahid Beheshti University of Medical Sciences Tehran University of Medical Sciences Imperial College London Children's Medical Center

About

Majid Marjani is an author at Masih Daneshvari Hospital specializing in medicine, tuberculosis, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	22	39	1.3K
2	Public Health	6	6	165
3	Health Sciences	5	5	116
4	Nursing	1	1	25
5	Allergy	1	1	15

Majid Marjani

Publications

2.3K

Citations

H-Index

Page 1

	Year	Citations
Diabetes mellitus and tuberculosis facts and controversies Parvaneh Baghaei, Majid Marjani, Pedram Javanmard, Journal of Diabetes & Metabolic Disorders	2013	176
No clinical benefit of high dose corticosteroid administration in patients with COVID-19: A preliminary report of a randomized clinical trial Hamidreza Jamaati, Seyed MohammadReza Hashemian, Behrooz Farzanegan, European Journal of Pharmacology Randomized Clinical TrialLong CovidPreliminary ReportCovid-19 PandemicClinical Benefit	2021	100
Increased Serum Levels of Soluble TNF-α Receptor Is Associated With ICU Mortality in COVID-19 Patients Esmaeil Mortaz, Payam Tabarsi, Hamidreza Jamaati, Frontiers in Immunology	2021	89
First-line anti-tuberculosis drug resistance patterns and trends at the national TB referral center in Iran—eight years of surveillance Masoud Shamaei, Majid Marjani, Ehsan Chitsaz, International Journal of Infectious Diseases	2009	84
Evaluating the effects of Intravenous Immunoglobulin (IVIg) on the management of severe COVID-19 cases: A randomized controlled trial Payam Tabarsi, Saghar Barati, Hamidreza Jamaati, International Immunopharmacology Long CovidIntravenous ImmunoglobulinCovid-19 PandemicCovid-19 EpidemiologyInfection Control	2020	83
Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial Farzaneh Dastan, Seyed Alireza Nadji, Ali Saffaei, International Immunopharmacology Non-controlled Prospective TrialCovid-19 PandemicImmunologyAntiviral TherapyInterferon Beta-1a	2020	80
Immunologic Features in Coronavirus Disease 2019: Functional Exhaustion of T Cells and Cytokine Storm Shima Mahmoudi, Mitra Rezaei, Nahal Mansouri, Journal of Clinical Immunology Coronavirus Disease 2019Viral PersistenceViral PathogenesisImmunologyAntiviral Response	2020	64
Adverse Effects of Multidrug-Resistant Tuberculosis Treatment With a Standardized Regimen: A Report From Iran Parvaneh Baghaei, Payam Tabarsi, Donna Dorriz, American Journal of Therapeutics Tuberculosis PreventionPharmacotherapyAntimicrobial ChemotherapyAdverse Drug ReactionDrug Resistance	2010	57
Plasmapheresis reduces cytokine and immune cell levels in COVID-19 patients with acute respiratory distress syndrome (ARDS) Seyed Mohammad Reza Hashemian, Navid Shafigh, Golnaz Afzal, Pulmonology Acute Lung InjuryInflammatory Lung DiseaseRespiratory Distress Syndrome (Pulmonary Critical Care)Lung InflammationImmunology	2020	56
Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial Farzaneh Dastan, Ali Saffaei, Sara Haseli, International Immunopharmacology Covid-19 PandemicImmunologyClinical TrialsAntiviral TherapyImmunotherapy	2020	54

Page 1